AGTR2 appears, therefore, as a potential therapeutic target for this disease, which would be in line with previous studies showing that the blockade of the renin–angiotensin system in mice55 and in humans56 prevents the onset of T2D, and restores normoglycemia57, 58. This evidence concerns the gene AGTR2 and type 2 diabetes mellitus.